Semaglutide (Novo Nordisk)

AstraZeneca and insitro will work in tandem to discover and develop drugs for cardiometabolic diseases, namely MASH and cardiomyopathies. Credit: Tada Images / Shutterstock.com. AstraZeneca has inked a billion-dollar artificial intelligence (AI)-powered drug discovery partnership and licensing deal with insitro, to identify novel targets and therapies for a range of cardiometabolic diseases. Through this partnership, the pair will focus on creating drugs to fulfil unmet needs and address the underlying drivers of disease in both metabolic dysfunction-associated steatohepatitis (MASH) and heart muscle-impacting cardiomyopathies. In exchange for an upfront payment of $40m and around $1.46bn in potential development and commercial milestones, AstraZeneca will secure the exclusive global rights to develop selected programmes developed through this partnership. The UK-Swedish pharma giant will also award insitro single-digit royalties on global sales of the fruits of this collaboration, provided they make it to market. At the heart of this partnership is insitro’s Virtual Human AI platform trained on large-scale human and cellular data, which the biotech uses to identify causal disease biology. According to insitro’s founder and CEO, Daphne Koller, applying AI to complex datasets around MASH and cardiomyopathies can allow the pair to “unlock greater discovery power” and reveal new insights into the genetics behind such diseases. “Our platform simultaneously deconvolutes disease biology and identifies causal drivers of disease pathologies,” Koller commented, adding that pairing expertise with AstraZeneca will allow the duo to scale with the potential to more rapidly progress novel programmes through the development stages to patients. AstraZeneca targets increasingly lucrative MASH arena AstraZeneca forges its collaboration as the company looks to deepen its legacy in the cardiovascular, renal and metabolic (CVRM) segment. Currently, the pharma giant has a plethora of marketed medicines in this disease area – including blockbuster SGLT2 inhibitor, Farxiga (dapagliflozin), which is now subject to generic erosion due to its US loss of market exclusivity earlier this year. It also marks a doubling down on AstraZeneca’s intent to enter the MASH market, as it is currently exploring the potential of a small molecule FAP inhibitor, AZD2389, in Phase II trials. The company hopes it will demonstrate better efficacy than its former antisense oligonucleotide MASH candidate, AZD2693, which it scrapped after it produced lacklustre results in a Phase II study. AstraZeneca makes moves toward the MASH market as it becomes increasingly lucrative, with a recent report from GlobalData, parent company of Pharmaceutical Technology, forecasting that the segment will balloon from a value of $802.3m in 2022 at a compound annual growth rate (CAGR) of 38.2% to a value of $20.3bn by 2032. This growth, analysts say, will primarily be fuelled by the anticipated launch of several pipeline candidates and uptake of established drugs such as Madrigal Pharmaceutical’s first-to-market Rezdiffra (resmetirom) and Novo’s blockbuster glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy, Wegovy (semaglutide) , as well as an anticipated uptick in the use of non-invasive tests for diagnosing and managing the disease. With this shifting MASH landscape, GlobalData analysts also point to burgeoning competition in this space, the flames of which are stoked by the potential emergence of further incretin therapies and alternative investigational antifibrotics on the market.

Di-tert-butyl dicarbonate (Boc₂O, CAS: 24424-99-5) is often simply described as an “amine protecting reagent,” but in the eyes of pharmaceutical R&D engineers, it is the driving force behind numerous blockbuster drugs. Shunxiang Pharmaceutical has combed through publicly available data from overseas journals and patents to show how this classic reagent underpins the synthetic routes of several star drugs. GLP-1 Weight-Loss and Anti-Diabetic Drugs Semaglutide (Ozempic/Wegovy) and tirzepatide (Zepbound/Mounjaro), both GLP-1 receptor agonists, are among the most closely watched metabolic drugs worldwide. In their solid-phase synthesis, the ε-amino group of the lysine side chain is commonly protected using the Boc strategy, with Fmoc-Lys(Boc)-OH and Boc-Lys(Boc)-OH recognized as key intermediates; European Patent EP3398960 also explicitly records the use of Boc-type amino acids such as Boc-His(Trt)-OH as raw materials for the preparation of semaglutide. Stable under basic coupling conditions and readily cleaved by acid, the Boc group precisely meets the needs of stepwise assembly and side-chain modification of long-chain peptides. Anti-Cancer Drug Docetaxel Docetaxel (Taxotere) is a classic anti-tumor drug. According to the Journal of Organic Chemistry, its key chiral side chain can be efficiently constructed from Boc-benzylamine in just three steps via dilithiation, enal addition, and oxidation. Here, Boc serves not only as an amine protecting group but also stabilizes the key intermediate through negative charge on nitrogen, providing a concise route to stereoselective synthesis of the side chain, delivering an esterification-ready side chain skeleton from Boc-benzylamine in only three steps. Anti-Viral Drug Intermediates In the synthesis of the HCV NS3 protease inhibitor BILN 2061 reported by Boehringer Ingelheim in the Journal of Organic Chemistry, the key building block vinyl-ACCA (1-amino-2-vinylcyclopropanecarboxylic acid) was prepared via a route based on Boc-protected glycine derivatives, achieving enantiomeric purity exceeding 99% ee and successful multikilogram scale-up—a representative case of the Boc strategy supporting industrial production of complex unnatural amino acids. Antibiotic and Anti-Diabetic Drug Intermediates In the cephalosporin field, the 7β-Boc-amino cephalosporin intermediates (Boc-ACLE and Boc-ACLH) are constructed in one step via Boc protection with SiO₂ catalysis and ultrasonic assistance, achieving isolated yields of 96% and 96.2%, respectively (Journal of Chemistry). The key intermediate of DPP-4 class anti-diabetic drugs (e.g., sitagliptin), 3-(R)-Boc-amino-4-(2,4,5-trifluorophenyl)butanoic acid, likewise relies on Boc-protected amino acid esters as core raw materials (Synthetic Communications). Conclusion From GLP-1 metabolic drugs to anti-tumor, anti-viral, and antibiotic products, Boc anhydride is deeply embedded in modern drug synthesis chains through its mild and controllable protecting-group chemistry. Shunxiang Pharmaceutical supplies high-purity di-tert-butyl dicarbonate with consistent batch quality and controlled impurities, providing reliable support for peptide and pharmaceutical intermediate production.